FACTS ABOUT MRTX1133 PDAC REVEALED

The identification of KRASG12C inhibitors has reignited curiosity in targeting RAS proteins. This work describes the discovery of the KRASG12D-particular inhibitor MRTX1133 and demonstrates the feasibility of potently and selectively focusing on this oncogenic variant.And clinical trials of blend therapy with KRAS G12C inhibitors and immune checkpo